Loading…
Reported covered position: Chief of Staff Rep. Harris; Asst. to Rep. Harris, House Cmte on Approps; Dep. Asst. Sec and Chief of Staff HHS/Asst. Secretary for Preparedness and Response (ASPR)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Support for novel HIE therapeutics.
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REVAGENIX, INC. via
Source: Senate LDA
| COHERUS BIOSCIENCES |
| 5 |
| 2023–2024 |
| AGILITI HEALTH INC. | 4 | 2026 |
| ATEA PHARMACEUTICALS, INC. | 4 | 2023–2024 |
| BRIGHT PATH LABORATORIES, INC. | 4 | 2026 |
| KIRIN BIOMATERIALS | 3 | 2026 |
| PARATEK PHARMACEUTICALS, INC. | 2 | 2023 |
| ACADIA PHARMACEUTICALS INC | 1 | 2023 |
| THE COALITION FOR ACCESS TO PRENATAL SCREENING | 1 | 2023 |
2026 · third_quarter · Q3
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRIGHT PATH LABORATORIES, INC. via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Policies that promote domestic pharmaceutical manufacturing.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
KIRIN BIOMATERIALS via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Support for the manufacture of bulk pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGILITI HEALTH INC. via THE CONAFAY GROUP, LLC
2026 · third_quarter · 3T
Advocacy for health care supply & medical devices and legislation about emergency preparedness and response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KIRIN BIOMATERIALS via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Support for the manufacture of bulk pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGILITI HEALTH INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Advocacy for health care supply & medical devices and legislation about emergency preparedness and response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHT PATH LABORATORIES, INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Policies that promote domestic pharmaceutical manufacturing.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Patient access to novel HIE therapeutics.
Support for novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KIRIN BIOMATERIALS via THE CONAFAY GROUP, LLC
2026 · second_quarter · RR
Support for the manufacture of bulk pharmaceuticals.
BRIGHT PATH LABORATORIES, INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Policies that promote domestic pharmaceutical manufacturing.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
AGILITI HEALTH INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Advocacy for health care supply & medical devices and legislation about emergency preparedness and response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Support for novel HIE therapeutics.
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY27 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AGILITI HEALTH INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · RR
Advocacy for health care supply & medical devices and legislation about emergency preparedness and response.
BRIGHT PATH LABORATORIES, INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · RR
Policies that promote domestic pharmaceutical manufacturing.
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Patient access to novel HIE therapeutics.
Support for novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Patient access to novel HIE therapeutics.
Support for novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · second_quarter · 2A
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · 1A
Patient access to novel HIE therapeutics.
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2025 · third_quarter · 3T
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Patient access to novel HIE therapeutics.
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · RR
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY25 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · RR
Advocating for patient access to novel HIE therapeutics.
Advocating for patient access to novel HIE therapeutics.
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY25 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · RR
Advocacy for medical countermeasure funding and support
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2024 · second_quarter · 2T
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · first_quarter · RR
Medical countermeasure management.
Medical countermeasure management.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PARATEK PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · 4T
Procurement of novel antibiotic.
Procurement of novel antibiotic.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PARATEK PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Procurement of novel antibiotic.
Procurement of novel antibiotic.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE COALITION FOR ACCESS TO PRENATAL SCREENING via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for access to prenatal testing.
Filing targets: HOUSE OF REPRESENTATIVES
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Pharmaceutical research/Medicare and Medicaid Reform.
Pharmaceutical research/Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE